Anti-tumor Effect Of RhuMAB HER2 Monoclonal Antibody On Individual Osteosarcoma Bearing Nude Mice

[Purpose] To observe the inhibition of RhuMAB HER2 monoclonal antibody (Herceptin) on implantation human osteosarcoma cells and provide experimental evidence for clinical use of Herceptin.(Methods] The levels of samples were investigated quantitatively by using molecular biological, immunological and pathological techniques. (1) 15 nude mice were divided into 3 groups: Implanting human osteosarcoma cells on nude mice to set up animal models of tumor in group A. Mice in group B and C were injected with DMEM and saline as control. Common conditions, tumor growth and changes of pathological indexes were detected. (2) Each mouse was injected with osteosarcoma cells. After 11 days,tumor bodies formed. 40 nude mice were divided into 4 groups: tumor-bearing immune therapy group, tumor-bearing combination therapy group, tumor-bearing chemotherapy group, tumor-bearing control group. Clinical, pathological and immunological indexes were detected.[Results] (l)Tumor bodies grew well in group A .Mice injected with DMEM and saline had no tumors. The level of AKP in group A was higher than that in group B and C. Pathological examination showed sarcoma cells with osteoid tissue. Viematin immunohistochemestry examination was positive. (2)There is no significantdifference between group A treated purely with Herceptin and group D injected with saline (p>0.05). The difference of tumor size and volume was not significant between the group treated with HD-MTX and combined therapy. But inhibiting effect of group B and C is more significant than that of group A and D in statistics.Conclusion] It is a good method to implant human osteosarcoma cells on nude mice to set up animal models of tumor for further study. During the procedure of human osteosarcoma cells transfering of culture by microscopic examination, the structure ingredient and differentiate degree kept the characteristics of human osteosarcoma cells. This model had short incubation period, average incubation period 11 days. Herceptin had not inhibition on primary osteosarcoma. Herceptin had not significant synergistic action with HD-MTX on primary osteosarcoma.